Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
Top Cited Papers
- 7 November 2012
- Vol. 63 (1), 72-79
- https://doi.org/10.1136/gutjnl-2012-303376
Abstract
Objective The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the introduction of these drugs. We aimed to assess the healthcare costs and productivity losses in a large cohort of IBD patients. Design Crohn's disease (CD) and ulcerative colitis (UC) patients from seven university hospitals and seven general hospitals were invited to fill-out a web-based questionnaire. Cost items were derived from a 3 month follow-up questionnaire and categorised in outpatient clinic, diagnostics, medication, surgery and hospitalisation. Productivity losses included sick leave of paid and unpaid work. Costs were expressed as mean 3-month costs per patients with a 95% CI obtained using non-parametric bootstrapping. Results A total of 1315 CD patients and 937 UC patients were included. Healthcare costs were almost three times higher in CD as compared with UC, €1625 (95% CI €1476 to €1775) versus €595 (95% CI €505 to €685), respectively (pConclusions We showed that healthcare costs are mainly driven by medication costs, most importantly by anti-TNFα therapy. Hospitalisation and surgery accounted only for a minor part of the healthcare costs.Keywords
This publication has 29 references indexed in Scilit:
- Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's diseaseGut, 2011
- Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM StudyGastroenterology, 2008
- The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative ColitisJournal of Occupational and Environmental Medicine, 2008
- Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up EvaluationGastroenterology, 2006
- Costs of Inflammatory Bowel Disease in GermanyPharmacoEconomics, 2006
- Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective studyGut, 2004
- Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and SurgeriesThe American Journal of Gastroenterology, 2004
- Burden of illness of Crohn’s disease in SpainDigestive and Liver Disease, 2003
- Long-Term Evolution of Disease Behavior of Crohn's DiseaseInflammatory Bowel Diseases, 2002
- Inflammatory bowel diseases: health care and costs in Sweden in 1994.Scandinavian Journal of Gastroenterology, 1997